AstraZeneca Q3 Results - Q3 Top Pharma Company Earnings Reports

View AstraZeneca's Q3 Earnings Report

FiercePharma says: AstraZeneca posted strong third-quarter numbers and boosted its full-year forecast by a whopping 40 cents per share. But one of the biggest pieces of news to come out of the company's Q3 report is a $520 million tentative agreement with the U.S. Attorney's Office in Philadelphia. Like several other drugmakers who've announced big settlements this year, AstraZeneca was facing a probe into alleged off-label marketing of a drug. In this case, the antipsychotic Seroquel. Read more of our coverage here...

Highlights:

  • US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.
  • US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER.
  • Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.

Check out AZ's current earnings estimates from CNN Money

AZ's Website: http://www.astrazeneca.com/

AstraZeneca Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

Dogged by opioid liabilities, Mallinckrodt is reportedly looking to restructure its U.S. generics unit to cover its debts and possible settlements.

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.